On January 16, 2019, Shenyang Hongqi Pharmaceutical Co., Ltd. ("Hongqi Pharmaceutical"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharmaceutical"), received a certificate from the State Drug Administration Regarding Rifampicin Capsules (Specification: 0.3g) "Drug Supplementary Application Approval Document" (Lot Number: 2019B00012), this drug was the first to pass the generic drug consistency evaluation.

The announcement shows that rifampicin capsules are mainly suitable for the treatment of various types of sensitive tuberculosis, asymptomatic Neisseria meningitidis carriers, and sensitive nontuberculous mycobacterial infections. In 2018, Hongqi Pharmaceutical's rifampicin capsules (specification: 0.3g) had no sales. As of December 2018, Fosun Pharma and its holding subsidiaries/units have invested approximately RMB 8.29 million in R&D expenses (unaudited) for the consistency evaluation of rifampicin capsules at this stage. The drug belongs to the 289 base drug catalog, which is conducive to market sales.

Hongqi Pharmaceutical currently has two products that have passed the consistency evaluation for the first time in the country, namely 0.3g rifampicin capsules and pyrazinamide tablets (specifications: 0.25g, 0.5g). As a subsidiary of Fosun Pharmaceuticals, Hongqi Pharmaceuticals has always taken independent innovation as the driving force for corporate development, and continued to improve the drug R&D and innovation system of “combination of imitation and innovation”. At the same time, it has been conducting drug consistency studies in strict accordance with national requirements to improve drug performance. Safety and effectiveness, to ensure the safety and effectiveness of drugs used by the people, and to help the country achieve the goal of ending tuberculosis by 2035 as soon as possible.